Navigation Links
Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Date:11/6/2013

SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia. Polaris Group is conducting clinical trials on ADI-PEG 20 for the treatment of several other indications, including hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.

(Logo: http://photos.prnewswire.com/prnh/20131106/LA12039LOGO)

"Data from our collaborators show that acute myeloid leukemia cells require the amino acid arginine for growth, and that deprivation of arginine by ADI inhibits leukemia cell growth," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "Treatment options for patients who have this form of leukemia are limited. We are pleased that the first patient in this trial has been treated with ADI-PEG 20 and we hope that ADI-PEG 20 will be of benefit to patients in this trial."

About ADI-PEG 20
ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group
Polaris Group is a privately held biopharmaceutical company
'/>"/>

SOURCE Polaris Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
2. GSI Group Announces Financial Results for the Third Quarter 2013
3. CAO Group Launches New Pilot Diode Laser System
4. Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
5. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
6. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
7. Securus Medical Group Raises $6.5M, Appoints New CEO
8. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
9. Long Island Plastic Surgical Group (LIPSG) Nominated in Four Categories for Best of Long Island 2014 Awards
10. Private Hospital Group in Spain Expands Radiotherapy Capabilities with Countrys First Elekta Versa HD System
11. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015  Xcelience, a contract development ... has made a structured cash investment in Powdersize, ... in milling, micronization and powder size classification within ... Powdersize,s business while simultaneously adding a complete set ... of capabilities. "As we continue ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Calif., Feb.16, 2012   HealthWarehouse.com , Inc. (OTC: HEWA), ... MedLion , Inc., a pioneering direct primary care ... and uninsured people in the Bay Area, Central Coast ... their homes. Nearly seven million Californians lacked ...
... KING OF PRUSSIA, Pa., Feb. 16, 2012 Medical ... the first fully-monitored medical alarm system that allows the ... today provides investors with an update on current initiatives. ... Inc. CFO and President, Ronald Adams. "We ...
Cached Medicine Technology:HealthWarehouse.com Partners With MedLion to Bring Affordable Healthcare to Northern California 2HealthWarehouse.com Partners With MedLion to Bring Affordable Healthcare to Northern California 3Medical Alarm Concepts Investor Update -- News on Current Initiatives 2Medical Alarm Concepts Investor Update -- News on Current Initiatives 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture ... community as well as tried-and-true products that have stood the test of time. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for authentic ... at Grant Park. The festival will end on Sunday, August 2nd. ... the annual Lollapalooza. This unique and unbelievably popular festival attracts the best in ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source ... launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and ... Prep from MDLinx makes preparing for the exam easy and painless. MDLinx offers ...
(Date:7/31/2015)... (PRWEB) , ... July 31, ... ... Jason T. Brown’s live lecture on pharmaceutical negligence is now available online ... was well received with a 94% approval rating from the nationwide audience. ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... , ST. LOUIS, Nov. 20 Centene ... will present at the Bank of America Merrill Lynch 2009 ... Crowne Plaza Hotel Times Square in New York City. , ... Time. Investors and other interested parties may access a live, ...
... Nov. 20 Samuel Gladding is no Scrooge, but he ... be "happy" during the holidays. As a licensed professional counselor ... Department of Counseling at Wake Forest University, Gladding says research ... often leads to sadness and even depression during the holidays. ...
... , , NEW YORK, Nov. ... announced that it will broadcast Doctor Radio Reports: What ... by veteran journalist Perri Peltz. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) , ... About Mammograms will air November 21 live at 10:00 ...
... durations of exposure to formaldehyde used for embalming in ... of death from myeloid leukemia, according to a new ... of the National Cancer Institute . Previous studies ... cancer in anatomists, pathologists, and funeral industry workers, all ...
... Washington) November 20, 2009Emergency medical service (EMS) providers ... cardiac arrests each year. Only 5 to ... arrest survive. Better quality cardiopulmonary resuscitation (CPR) ... with better patient outcome. The Resuscitation Outcomes ...
... short as 34 weeks, potentially adding to preemie delivery rate, experts ... that the rate of preterm deliveries continues to climb in the ... Many women are confused about what constitutes a full-term birth in ... the study considered a baby born at 34 to 36 weeks ...
Cached Medicine News:Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
Medicine Products: